More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/MCC950 . Na [256373-96-3]
Chemical Structure
Chemical Structure
Chemical Structure

MCC950 . Na [256373-96-3]

Research Use Only
AG-CR1-3615
AdipoGen Life Sciences
CAS Number256373-96-3
DownloadMSDS
Product group Chemicals
Estimated Purity>97%
Molecular Weight426.5
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    MCC950 . Na
  • Delivery Days Customer
    10
  • CAS Number
    256373-96-3
  • Certification
    Research Use Only
  • Estimated Purity
    >97%
  • Hazard Information
    Warning
  • Molecular Formula
    C20H23N2NaO5S
  • Molecular Weight
    426.5
  • Scientific Description
    Chemical. CAS: 256373-96-3. Formula: C20H23N2NaO5S. MW: 426.5. Synthetic. Potent, selective and orally available NLRP3 inflammasome inhibitor. Blocks the release of IL-1beta in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3. Prevents oligomerization of ASC in cells stimulated with LPS and nigericin. Active in vivo, blocking the production of IL-1beta and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome. Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases. - Potent, selective and orally available NLRP3 inflammasome inhibitor. Blocks the release of IL-1beta in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3. Prevents oligomerization of ASC in cells stimulated with LPS and nigericin. Active in vivo, blocking the production of IL-1beta and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome. Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.
  • SMILES
    [NaH].CC(C)(O)C1=COC(=C1)S(=O)(=O)NC(=O)NC1=C2CCCC2=CC2=C1CCC2
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing: R.E. Laliberte, et al.; J. Biol. Chem. 278, 16567 (2003)
  • Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methylethyl)furan-2-sulfonyl]urea, an antiinflammatory agent: F.J. Urban, et al.; Synth. Commun. 33, 2029 (2003)
  • The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes: R.C. Coll, et al.; PLoS One 6, e29539 (2011)
  • A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases: R.C. Coll, et al.; Nat. Med. 21, 248 (2015)
  • Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015)
  • The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015)